Corporate Profile

CalciMedica is a clinical-stage biopharmaceutical company advancing calcium release-activated calcium (CRAC) channel inhibitors to address serious inflammatory, immunologic and cardiopulmonary diseases.

Our pipeline includes two distinct investigational compounds: zegocractin, administered intravenously as Auxora™, and CM5480, an oral candidate intended for chronic dosing. Auxora has been evaluated in more than 350 patients. Its development plans include a Phase 1b proof-of-concept trial in pulmonary arterial hypertension and a Phase 2b trial in acute pancreatitis. Initiation of the acute pancreatitis trial is subject to additional financing. CM5480 is being developed for pulmonary hypertension, with an Investigational New Drug (IND) application submission anticipated in mid-2027.

Learn More

Stock Information

Minimum 15 minutes delayed. Source: LSEG

Featured Events

More events are coming soon.
View all Events

Corporate Presentation

View Presentation

Press Releases

08 Sep 26

CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and
27 Aug 26

CalciMedica Announces One-for-Five Reverse Stock Split

CalciMedica’s Common Stock to Begin Trading on a Post-Split Adjusted Basis on August 31, 2026 LA JOLLA, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated
11 Aug 26

CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

Completed private placement financing of up to approximately $49 million to advance pulmonary hypertension program Auxora Phase 1b proof-of-concept data in pulmonary arterial hypertension (PAH) and CM5480 IND submission both anticipated in mid-2027 FDA aligned that the primary endpoint for the
29 Jul 26

CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints

FDA aligned on new-onset severe respiratory failure as the Phase 2b primary endpoint, with multi-organ failure and time to medically indicated discharge as key secondary endpoints FDA aligned on a strategy to evaluate elevated lactate dehydrogenase (LDH) as a potential enrichment marker for
View all Releases
Explore More
Our Technologies
Our Pipeline
About Us
Our Team